Melanoma has proven resistant to most available chemotherapy and immunotherapy.
Introduction
There has been little progress over the past 30 years in the medical treatment of metastatic melanoma. It is largely unresponsive to available chemotherapy [1*] and shows low response rates to a number of different biologic agents such as interleukin-2, interferon-α2 and melanoma vaccines [2] . Although different forms of chemotherapy have a number of biochemical targets, it is generally believed that chemotherapy kills cancer cells by induction of a final common pathway that leads to programmed cell death or apoptosis [3] [4] [5] . Better understanding of this process is gradually providing insights into the resistance of melanoma to treatment [6, 7] and how this may lead to development of new treatment approaches based on activation of the apoptotic pathways.
The agents that are commonly used against melanoma act by damaging cellular components -for example, by methylating guanine (dacarbazine/temozolomide), crosslinking DNA (cisplatin) or damaging microtubules (taxols, vinblastine) -to such an extent that apoptosis is induced. Traditionally, two principal pathways to apoptosis have been recognized the transmembrane 'extrinsic' pathway and the mitochondrial 'intrinsic' pathway [8, 9] . Both depend on activation of cysteine proteases that cleave at aspartate residues (caspases). These enzymes are synthesized as proenzymes that become activated by adaptor proteins. Initiator caspases once activated can activate effector caspases, which act on a wide range of substrates to cause apoptosis. The initiator caspases for the extrinsic pathway are caspase 8 and 10, whereas caspase 9 and 2 are initiator caspases for the intrinsic pathway. The effector caspases are believed to be similar for both pathways: 3, 6 and 7.
Irrespective of whether apoptosis is initiated by the extrinsic or intrinsic pathway, apoptosis of most solid carcinomas is dependent on changes in mitochondria.
Mitochondria play a central role in energy-generating processes within the cell but, in addition, constitute a crucial source of products which facilitate apoptosis. These include the release of cytochrome c and other aptogenic proteins such as Smac/DIABLO or OMI [10*] . Cytochrome c binds to apoptotic protease activating factor-1 (Apaf-1) and this complex (the apoptosome) activates caspase 9 [11, 12] . Smac/DIABLO and OMI on the other hand facilitate apoptosis by binding to inhibitor of apoptosis proteins (IAPs), which bind to and inhibit effector caspases.
Members of the B cell lymphoma protein (Bcl)-2 family are critical regulators of the mitochondrial pathway to apoptosis and include both pro-survival (e.g. Bcl-2, Bcl-XL, Mcl-1) and pro-apoptotic proteins [13, 14] . The anti-apoptotic members of the Bcl-2 family function as guardians of mitochondrial integrity. Their anti-apoptotic activity can be inhibited by heterodimerization with some pro-apoptotic members. Multiple apoptotic stimuli have been shown to regulate the activity of Bcl-2 family members by different mechanisms involving transcription, proteolytic cleavage or phosphorylation [4, 5] . The pro-apoptotic proteins include Bax and Bak multidomain proteins, which share two to three Bcl-2 homology regions with the anti-apoptotic Bcl-2s and Bcl-2 homology region 3 (BH3) sensor proteins, which share only the BH3 homology region with the antiapoptotic proteins. Bax and Bak appear critical for induction of apoptosis in that Bax -1-
Bak
-1-cells do not undergo apoptosis in response to BH3 proteins [15, 16] [26, 27] . These concepts are illustrated in Fig. 1 . Many of the TNF family members may also trigger other signal pathways that activate anti-apoptotic pathways, for example, TRAIL was shown to activate nuclear factor-κB (NF-κB) [28] (which regulates several anti-apoptotic proteins) 6 and prosurvival pathways such as the mitogen activated protein kinase ERK1/2 pathway [19] .
Apoptosis is also regulated by another family of proteins referred to as IAPs [30] [31] [32] .
These include IAP 1 and 2. XIAP, ML-IAP and Survivin. In general they bind to caspases and prevent their activation (caspase 9) or inhibit their effector function (caspase 3, 7). They also have other roles as E3 ligases and in ubiquination of proteins for degradation by proteasomes [33*], as discussed elsewhere. Binding of IAPs to caspases is competitively inhibited by Smac/DIABLO and OMI released from mitochondria and this allows effector caspases to induce apoptosis. This mechanism was shown to be the principal pathway in TRAIL induced apoptosis of melanoma [34] .
It is apparent from the above that there is a considerable amount of information about induction of apoptosis in cancer cells and this has posed a challenge as to how this knowledge can be used to develop new treatment approaches against melanoma and other cancers. The following sections summarize the advances made and approaches being taken in this field, with particular emphasis on human melanoma (Table 1) .
Targeting the B cell lymphoma-2 family of anti-apoptotic proteins
Given the importance of Bcl-2 anti-apoptotic proteins in regulation of the mitochondrial pathway, much effort has been focused on agents that may decrease their activity. One of the first approaches was based on antisense methods against mRNA for the proteins.
Nuclease resistant antisense against Bcl-2 in melanoma was shown by Jansen et al. [35] to sensitize melanoma xenografts to chemotherapy with dacarbazine. Subsequent phase I studies in patients with the antisense agent oblimersen suggested it was associated with 7 similar effects in melanoma patients [36] . In view of this, Genta Inc. initiated a large randomized phase III study on 771 patients with metastatic melanoma, which was completed in August 2003. This showed a significant prolongation of progression free survival and overall response rate in patients treated with dacarbazine and oblimersen.
The primary endpoint of overall survival was not significantly different between the groups when all patients were included in the analysis but was significant when the analysis was confined to patients with normal lactate dehydrogenase levels (A. Bedikian et al., in preparation) [37] . (The latter measure is an indicator of more advanced disease.)
This particular trial was criticized on several procedural matters but more importantly it did not target treatment to patients with melanoma known to express Bcl-2. This was important as Bcl-2 expression is low or absent in many metastatic melanomas. In contrast to Bcl-2, the Mcl-1 protein was shown in immunohistological studies to be increased in metastatic melanoma compared with primary melanoma (Fig. 2) and both Bcl-2 and Bcl-XL [43] . Studies on melanoma xenografts in severe combined immunodeficient mice showed antisense to Mcl-1 to be effective in sensitizing melanoma to dacarbazine chemotherapy [38] . Similarly, antisense to Bcl-XL enhanced sensitivity of melanoma to chemotherapy [41] . Antisense to both Bcl-2 and Bcl-XL was also reported to have an anti-angiogenic effect [43] . Phase I/II studies are now required to assess their safety and pharmacological effects.
Small molecular weight inhibitors of B cell lymphoma 2 and XL proteins
The BH3 α-helix in the BH3-only proteins binds to a large hydrophobic pocket on the Gossypol is a naturally occurring compound in cotton seeds which was also shown to bind to the BH3 binding pocket of Bcl-2 and Bcl-XL. It may therefore be a promising agent to sensitize cells to chemotherapy and other agents [47] .
Inhibitors of inhibitor of apoptosis protein
The and in previously treated patients (Onyx/Bayer (117118 protocol)).
Ras is upstream of Raf and requires a farnesyl group to be attached for membrane anchorage. It may therefore be possible to inhibit the pathway with inhibitors of farnesyl transferase. These have shown antitumor activity in preclinical studies [61, 62] and sensitized human melanoma cells to cisplatin [63] but further evaluation is needed.
Phosphoinositide 3 kinase and Akt inhibitors
Phosphoinositide 3 kinase (PI3K) is activated by tyrosine kinase receptors such as the insulin receptors and leads to phosphorylation of Akt on threonine 308 via PDK1 [64] or serine 473 by the Rictor-mTOR (target of rapamycin) complex [65] .
Akt is constitutively activated in many melanoma cells [66, 67] and is able to suppress apoptosis via a number of mechanisms including phosphorylation of Forkhead transcription factors, which regulate several pro-apoptotic proteins such as Bim and Fas ligand. The phosphorylated Forkhead proteins are trapped in the cytosol and cannot enter the nucleus. Akt also phosphorylates and inactivates several pro-apoptotic proteins such as Bad and caspase 9 [64, 68] . Importantly, it activates IκB kinase (IKK) and thereby activates the transcription factor NF-κB, leading to transcription of several anti-apoptotic proteins such as Bcl-XL, AI and XIAP [69] .
Relatively few studies have been carried out with inhibitors of this pathway. PX-866 is a specific inhibitor of PI3K which was shown to have single agent activity and to enhance chemotherapy and radiation in preclinical studies [70] . Heat shock protein 90 (HSP90) is a chaperone for a number of signal proteins, including Akt and Raf. A geldanamycin derivative (17AAG) was shown to deplete Akt and cyclin D1 in melanoma lines [71, 72] .
Phase I studies have been conducted in patients with advanced malignancies and phase II studies on melanoma patients in the Memorial Sloan Kettering Institute are in progress.
A more soluble preparation, referred to as KOS-953, is about to enter clinical trials (Kosan Biosciences Inc.).
CCI-779, a rapamycin analogue, was tested in 33 patients with melanoma. Only one partial response was seen [73] but studies in combination with apoptosis inducing agents may be needed. Rapamycin was found to inhibit activation of NF-κB by doxorubicin but the mechanism of action appeared independent of PI3K [74] . Specific inhibitors of NF-κB activation do not appear to have been clinically evaluated but proteasome inhibitors such as PS-341/bortezomib have been thought to act by inhibiting activation of NF-κB and account for its effects in potentiating chemotherapy [75] and radiotherapy [76] .
Nevertheless, proteasome inhibitors affect a wide range of apoptosis regulators. One study in fact found no effect on NF-κB activity but instead apoptosis appeared to be due to upregualtion of Noxa [77] . A number of agents inhibit NF-κB activation in vitro, such as curcumin [78] , but are yet to be tested in vivo.
Activating the extrinsic pathway
The agents discussed above are also applicable to attempts to treat melanoma by agents such as TRAIL or Fas Ligand. These pathways have several additional obstacles that may need to be overcome. Principal among these is the low or absent death receptor expression on many melanomas, particularly on fresh isolates [79] . The main death receptor for TRAIL, TRAIL-R2 (DR5), was shown to be transcriptionally regulated by p53 and non-p53 dependent mechanisms as reviewed elsewhere [80] . In melanoma mRNA for the death receptors appeared at normal levels and non-transcriptional events appeared more important in regulation [81] . It was shown in TRAIL resistant colon carcinoma that TRAIL-R1 appeared located in the golgi and treatment with tunicamycin resulted in upregulation of TRAIL-R1 [82] . Similarly, tunicamycin was shown to upregulate TRAIL-R2 in prostate carcinoma cells [83] . These findings have been reproduced in cultured melanoma cells. Further studies are needed to investigate clinical applicability.
Conclusion
New treatment initiatives for metastatic melanoma prior to 2000 were largely based on testing new chemotherapy agents or combination of agents or various biological agents with or without chemotherapy. Research on apoptosis and other death pathways over the 13 past decade has, however, generated a wide range of new reagents which are designed primarily to enhance cell death induced by chemotherapy, radiation or immunotherapy.
Evaluations of these new agents are at an early stage and many are at the preclinical level.
This applies particularly to small molecular weight mimics of the Bcl-2 family and 18:1443-1450. This is a good review of current status.
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